Tuesday, 2 July 2013

Global IVIG Market Report 2013


ResearchMoz.us include new market research report "Global IVIG Market Report to 2013" to its huge collection of research reports.

In order to address the unmet medical needs related to blood disorders, autoimmune diseases and liver function impairment among others, associated companies are coming up with novel and improved treatment options like IVIG, albumin, clotting factors etc. which are derived from human blood plasma.


Intravenous immunoglobulin (IVIG) is a blood plasma derivative administered intravenously. It comprises of pooled, polyvalent, IgG (immunoglobulin (antibody) G) extracted from the plasma of more than one thousand blood donors. The very blood plasma derivative is deployed mainly in the treatment of autoimmune disorders, immune deficiencies and acute infections. IVIG has been the key factor to drive the growth of plasma products industry. The demand for IVIG has been growing on account of its increased usage in the treatment of primary immunodeficiency as well as newer neurological indications.

The present report offers an analysis of the global IVIG market with a special focus on the IVIG market of the US. The market is characterized by fast pace developments in the clinical technology and testing methodology. Despite challenges like stringent regulations and high cost of treatment, the global IVIG market is all set to witness high growth in the coming years as a result of growing ageing population, increasing number of patients with bleeding disorder, and rising health expenditure. Furthermore, the competitive landscape of the industry is highlighted. The rivalry prevalent in the global IVIG plasma market is quite fierce with numerous local and global players contenting for the market share. On the global front, the key players are Baxter, CSL, and Grifols.



Contact Us: 
Email: sales@researchmoz.us
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)